Menu

MIT Provost Steps Down

Chris Kaiser, a molecular biologist, leaves his administrative post to return to research and teaching.

Sep 18, 2013
Erin Weeks

WIKIMEDIA, JOHN PHELANAfter a little more than a year in the position, Chris Kaiser announced this week (September 16) that he will step down as provost of the Massachusetts Institute of Technology (MIT) in late October. Kaiser will return to “the rich and exciting intellectual life of an MIT faculty member,” he said.

Prior to serving as provost, Kaiser chaired the university’s biology department for eight years. He turned down an opportunity to lead the National Institute of General Medical Sciences in 2012 before accepting the administrative role at MIT.

“Since taking on the role of provost, Chris has served by my side through a challenging period for MIT,” President L. Rafael Reif wrote in an e-mail to the MIT community. Among other things, the university made headlines in the past year for its role in the prosecution of the late Aaron Schwartz.

Kaiser said that he plans to remain active in community engagement surrounding the Schwartz case and the university’s online education initiatives.

“As provost . . . I have been an enthusiastic cheerleader as the revolution in online learning sweeps across MIT,” he wrote. “But administration and cheerleading are not the same as doing. I am eager to return to the classroom and to actively participate in the development of new educational tools.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.